Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

Dr. Patrick J. Stiff

Hematology Oncology | Hematology | Oncology

2160 S First Ave, (luh-north Ent., Rm. 7604),

Maywood, IL

Clinical Trials:Currently Recruiting for 1 Trial

Accepting New Patients

46 Years of Experience

Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

2160 S First Ave, (luh-north Ent., Rm. 7604),

Maywood, IL

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Patrick Stiff is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Stiff has been practicing medicine for over 46 years and is rated as an Experienced provider by MediFind in the treatment of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Stiff is currently accepting new patients.

His clinical research consists of co-authoring 113 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Buckeye Health Plan

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE-MEDICAID PLAN

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Oscar

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 4 Less Insurance Carriers -

Locations

2160 S First Ave, (luh-north Ent., Rm. 7604), Maywood, IL 60153

Call: 708-216-3304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications

Enrollment Status: Recruiting

Publish Date: February 11, 2026

Intervention Type: Drug

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Enrollment Status: Active_not_recruiting

Publish Date: January 26, 2026

Intervention Type: Biological, Procedure

Study Drug: Rituximab

Study Phase: Phase 3

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

Enrollment Status: Completed

Publish Date: January 05, 2026

Intervention Type: Other

Study Phase: Not Applicable

A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Enrollment Status: Withdrawn

Publish Date: October 03, 2025

Intervention Type: Drug

Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin

Study Phase: Phase 1/Phase 2

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Enrollment Status: Terminated

Publish Date: August 28, 2025

Intervention Type: Drug

Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim

Study Phase: Phase 2

An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Enrollment Status: Completed

Publish Date: July 02, 2025

Intervention Type: Biological

Study Phase: Phase 3

A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies

Enrollment Status: Completed

Publish Date: April 06, 2025

Intervention Type: Drug, Other

Study Drug: Omidubicel

Study Phase: Phase 3

INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors After Hematopoietic Cell Transplantation

Enrollment Status: Completed

Publish Date: January 29, 2025

Intervention Type: Other

Study Phase: Phase 3

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma

Enrollment Status: Completed

Publish Date: January 14, 2025

Intervention Type: Drug, Biological

Study Drugs: Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel

Study Phase: Phase 2

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Enrollment Status: Completed

Publish Date: November 19, 2024

Intervention Type: Drug, Biological

Study Drugs: KTE-X19 Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine

Study Phase: Phase 1/Phase 2

Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells

Enrollment Status: Completed

Publish Date: October 23, 2024

Intervention Type: Genetic

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Enrollment Status: Terminated

Publish Date: July 10, 2024

Intervention Type: Drug

Study Phase: Phase 2

Safety, Efficacy and Feasibility of Haploidentical Stem Cell Transplantation (Haplo-SCT) Using Post-Transplant Cyclophosphamide (PTCy) as an Alternative Donor Source for Patients Who Lack a Matched Sibling/Unrelated Donor Options

Enrollment Status: Terminated

Publish Date: July 10, 2024

Intervention Type: Drug, Other

Study Drugs: Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil

Study Phase: Phase 2

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Enrollment Status: Completed

Publish Date: February 22, 2023

Intervention Type: Drug

Study Drugs: I-131-CLR1404, Dexamethasone

Study Phase: Phase 1

Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML

Enrollment Status: Terminated

Publish Date: February 08, 2023

Intervention Type: Drug

Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim

Study Phase: Phase 3

A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent

Enrollment Status: Terminated

Publish Date: September 26, 2022

Intervention Type: Drug

Study Drug: Rigosertib

Study Phase: Phase 3

An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia

Enrollment Status: Completed

Publish Date: September 27, 2018

Intervention Type: Biological

Study Phase: Phase 2

A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Enrollment Status: Terminated

Publish Date: August 13, 2018

Intervention Type: Drug

Study Phase: Phase 1

View 17 Less Clinical Trials

113 Total Publications

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.

Journal: Leukemia & lymphoma

Published: July 09, 2025

View All 113 Publications

Similar Doctors

Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

Dr. Kevin P. Barton

Hematology Oncology | Hematology | Oncology

Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

Dr. Kevin P. Barton

Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave,

Maywood, IL

(0.2 miles away)

708-216-9000

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Kevin Barton is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Barton is rated as a Distinguished provider by MediFind in the treatment of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. His top areas of expertise are Beta Thalassemia, Shwartzman Phenomenon, Non-Hodgkin Lymphoma, Aplastic Anemia, and Bone Marrow Aspiration. Dr. Barton is currently accepting new patients.

Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

Dr. Mark Karides

Hematology | Oncology

Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

Dr. Mark Karides

Hematology | Oncology

Illinois Cancer Specialists

7447 W Talcott Ave,

Chicago, IL

(9.1 miles away)

773-774-0042

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Mark Karides is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Karides is rated as a Distinguished provider by MediFind in the treatment of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. His top areas of expertise are Severe Congenital Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

Dr. Urszula Sobol

Hematology | Oncology

Experienced in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections

Dr. Urszula Sobol

Hematology | Oncology

Illinois Cancer Specialists, PC

880 W. Central Rd., Suite 8200,

Arlington Heights, IL

(16.6 miles away)

847-259-4482

Languages Spoken:

English

See accepted insurances

Urszula Sobol is a Hematologist and an Oncologist in Arlington Heights, Illinois. Dr. Sobol is rated as a Distinguished provider by MediFind in the treatment of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections. Her top areas of expertise are Familial Pancreatic Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Colorectal Cancer.

VIEW MORE PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDERS ASSOCIATED WITH STREPTOCOCCUS INFECTIONS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stiff's expertise for a condition

ConditionClose